Glycogen synthase kinase 3 (GSK3 ... Figure 5: Several signalling pathways induce the inhibition of GSK3 by phosphorylating the same serine residue near the amino terminus. Figure 6: The mechanism ...

In a notable study, researchers designed and synthesized novel compounds that act as dual inhibitors targeting both glutaminyl cyclase and glycogen synthase kinase-3β (GSK-3β), another enzyme ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen ...

07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of ...